Alterations in the Fungal Microbiome in Ulcerative Colitis
Inflammatory Bowel Diseases · 03.10.2023 · 29 (10) · 1613-1621
DOI: 10.1093/ibd/izad082 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.05.2023. Verfasst von Katie Hsia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Tufts Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Mycobiome, Gastrointestinal Microbiome, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
Although gut fungi have been implicated in the immunopathogenesis of inflammatory bowel disease, the fungal microbiome has not been deeply explored across endohistologic activity and treatment exposure in ulcerative colitis.
Methods
We analyzed data from the SPARC IBD (Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease) registry. We evaluated the fungal composition of fecal samples from 98 patients with ulcerative colitis across endoscopic activity (n = 43), endohistologic activity (n = 41), and biologic exposure (n = 82). Across all subgroups, we assessed fungal diversity and differential abundance of taxonomic groups.
Results
We identified 500 unique fungal amplicon sequence variants across the cohort of 82 patients, dominated by phylum Ascomycota. Compared with endoscopic remission, patients with endoscopic activity had increased Saccharomyces (log2 fold change = 4.54; adjusted P < 5 × 10-5) and increased Candida (log2 fold change = 2.56; adjusted P < .03). After adjusting for age, sex, and biologic exposure among patients with endoscopic activity, Saccharomyces (log2 fold change = 7.76; adjusted P < 1 × 10-15) and Candida (log2 fold change = 7.28; adjusted P< 1 × 10-8) remained enriched during endoscopic activity compared with quiescence.
Conclusions
Endoscopic inflammation in ulcerative colitis is associated with an expansion of Saccharomyces and Candida compared with remission. The role of these fungal taxa as potential biomarkers and targets for personalized approaches to therapeutics in ulcerative colitis should be evaluated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Tufts Medical Center, Boston, MA, USA.
- Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, MA, USA.
- Friedman School of Nutrition and Science Policy, Tufts University, Boston, MA, USA.
- Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA, USA.
- Division of Gastroenterology, Department of Medicine, University of California San Diego, San Diego, CA, USA.
- Division of Gastroenterology, Department of Medicine, Tufts Medical Center, Boston, MA, USA.
ORCID-Profile: Mei Chung, Sushrut Jangi
Förderung
- NCATS NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
- Tufts University School of Medicine
Zitieren
APA
Hsia, K., Zhao, N., Chung, M., Algarrahi, K., Montaser Kouhsari, L., Fu, M., Chen, H., Singh, S., Michaud, D. S., & Jangi, S. (2023). Alterations in the Fungal Microbiome in Ulcerative Colitis. Inflammatory Bowel Diseases, 29(10), 1613-1621. https://doi.org/10.1093/ibd/izad082
Vancouver
Hsia K, Zhao N, Chung M, Algarrahi K, Montaser Kouhsari L, Fu M, et al. Alterations in the Fungal Microbiome in Ulcerative Colitis. Inflammatory Bowel Diseases. 2023;29(10):1613-1621. doi:10.1093/ibd/izad082
BibTeX
@article{Hsia2023,
author = {Hsia, Katie and Zhao, Naisi and Chung, Mei and Algarrahi, Khalid and Montaser Kouhsari, Laleh and Fu, May and Chen, Hannah and Singh, Siddharth and Michaud, Dominique S and Jangi, Sushrut},
title = {Alterations in the Fungal Microbiome in Ulcerative Colitis},
journal = {Inflammatory Bowel Diseases},
year = {2023},
volume = {29},
number = {10},
pages = {1613--1621},
doi = {10.1093/ibd/izad082}
}
EUVIMED